Disease on EC 1.1.1.146 - 11beta-hydroxysteroid dehydrogenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
11beta-hydroxysteroid dehydrogenase deficiency
11beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension.
11beta-hydroxysteroid dehydrogenase type 1 deficiency ('apparent cortisone reductase deficiency') in a 6-year-old boy.
A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia.
Cortisol metabolism in the postoperative period after cardiac surgery.
Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.
Enhanced hippocampal long-term potentiation and spatial learning in aged 11beta-hydroxysteroid dehydrogenase type 1 knock-out mice.
Epidemiologic study of adrenal gland disorders in Japan.
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
Genetics of hypertensive syndrome.
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue.
Low doses of liquorice can induce hypertension encephalopathy.
Pubertal presentation of congenital delta 5-3 beta-hydroxysteroid dehydrogenase deficiency.
Regulation of the genes for 11beta-hydroxysteroid dehydrogenase type 1 and type 2 in the kidney of the Dahl rat.
Renin-Independent hypermineralocorticoidism.
Steroid metabolism in metabolic syndrome X.
The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes.
3alpha(or 20beta)-hydroxysteroid dehydrogenase deficiency
11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.
11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response.
A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome.
Apparent cortisone reductase deficiency: a functional defect in 11beta-hydroxysteroid dehydrogenase type 1.
Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase.
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
Genotypes at 11beta-hydroxysteroid dehydrogenase type 11B1 and hexose-6-phosphate dehydrogenase loci are not risk factors for apparent cortisone reductase deficiency in a large population-based sample.
Lack of Association of the 11beta-hydroxysteroid dehydrogenase type 1 gene 83,557insA and hexose-6-phosphate dehydrogenase gene R453Q polymorphisms with body composition, adrenal androgen production, blood pressure, glucose metabolism, and dementia.
Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency.
Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency.
Acidosis
Effects of changes in dietary intake of sodium and potassium and of metabolic acidosis on 11beta-hydroxysteroid dehydrogenase activities in rat kidney.
Effects of sustained hypoxaemia with 72 hours recovery on 11beta-hydroxysteroid dehydrogenase types 1 and 2 gene expression in near-term fetal sheep.
Acromegaly
Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma.
Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
Modulation of cortisol metabolism during treatment of acromegaly is independent of body composition and insulin sensitivity.
Urinary steroid excretion rates in acromegaly.
ACTH Syndrome, Ectopic
Apparent mineralocorticoid excess syndrome: an overview.
ACTH-Secreting Pituitary Adenoma
Effects of Carbenoxolone on the Canine Pituitary-Adrenal Axis.
Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
Inhibition of 11beta-hydroxysteroid dehydrogenase eliminates impaired glucocorticoid suppression and induces apoptosis in corticotroph tumor cells.
Acute Lung Injury
Inflammatory mediators down-regulate 11beta-hydroxysteroid dehydrogenase type 2 in a human lung epithelial cell line BEAS-2B and the rat lung.
Addison Disease
Epidemiologic study of adrenal gland disorders in Japan.
Adenocarcinoma
Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas.
Regulation of 11beta-hydroxysteroid dehydrogenase type 2 by steroid hormones and epidermal growth factor in the Ishikawa human endometrial cell line.
Adenoma
11beta-Hydroxysteroid dehydrogenase types 1 and 2 are up- and downregulated in cortisol-secreting adrenal adenomas.
A case of cortisol producing adrenal adenoma without phenotype of Cushing's syndrome due to impaired 11beta-hydroxysteroid dehydrogenase 1 activity.
Cortisol-secreting adrenal adenomas express 11beta-hydroxysteroid dehydrogenase type-2 gene yet possess low 11beta-HSD2 activity.
Expression of 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma.
Human adrenal cortex and aldosterone secreting adenomas express both 11beta-hydroxysteroid dehydrogenase type 1 and type 2 genes.
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Role of local 11 beta-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas.
Role of local 11beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) expression in determining the phenotype of adrenal adenomas.
Adrenal Hyperplasia, Congenital
11Beta-Hydroxylase Deficiency and Other Syndromes of Mineralocorticoid Excess as a Rare Cause of Endocrine Hypertension.
Effect of carbenoxolone on the plasma renin activity and hypothalamic-pituitary-adrenal axis in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective 11beta-hydroxysteroid dehydrogenase reductase activity.
Genetics of hypertensive syndrome.
Adrenal Insufficiency
Effect of growth hormone deficiency and recombinant hGH (rhGH) replacement on the hypothalamic-pituitary-adrenal axis in children with idiopathic isolated GH deficiency.
Mechanism of adrenal insufficiency following trauma and severe hemorrhage: role of hepatic 11beta-hydroxysteroid dehydrogenase.
Placental 11beta-HSD2 activity, early postnatal clinical course, and adrenal function in extremely low birth weight infants.
The role of progesterone metabolism and androgen synthesis in renal blood pressure regulation.
Adrenocortical Adenoma
Cortisol-secreting adrenal adenomas express 11beta-hydroxysteroid dehydrogenase type-2 gene yet possess low 11beta-HSD2 activity.
Adrenocortical Carcinoma
Expression of 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma.
Uneventful delivery following series of successive treatments for virilized Cushing syndrome due to adrenocortical carcinoma.
Adrenogenital Syndrome
[Unusual adrenogenital syndrome. Probable blockade of 3 beta-hydroxysteroid dehydrogenase in a 4-year-old boy]
Albuminuria
Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function.
Alkalosis
Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.
Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene.
Alopecia
delta 5-3 beta-hydroxysteroid dehydrogenase activity in sebaceous glands of scalp in male-pattern baldness.
Alzheimer Disease
Quantitative measurements of corticosteroids in ex vivo samples using on-line SPE-LC/MS/MS.
Arthritis
Arthritis and endogenous glucocorticoids: the emerging role of the 11beta-HSD enzymes.
Local metabolism of glucocorticoids and its role in rat adjuvant arthritis.
Arthritis, Experimental
Local metabolism of glucocorticoids and its role in rat adjuvant arthritis.
Arthritis, Rheumatoid
Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation.
Asthma
Clinical relevance of airway 11beta-hydroxysteroid dehydrogenase type II enzyme in asthma.
Effect of inhaled glucocorticoid treatment on placental 11beta-hydroxysteroid dehydrogenase type 2 activity and neonatal birthweight in pregnancies complicated by asthma.
Metabolism of synthetic steroids by the human placenta.
Postmenopausal asthma: the estradiol 11beta-hydroxysteroid dehydrogenase connection.
Reduced 11beta-hydroxysteroid dehydrogenase type 2 activity is associated with decreased birth weight centile in pregnancies complicated by asthma.
Atherosclerosis
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
7-oxysterols modulate glucocorticoid activity in adipocytes through competition for 11beta-hydroxysteroid dehydrogenase type.
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Human and rodent type 1 11beta-hydroxysteroid dehydrogenases are 7beta-hydroxycholesterol dehydrogenases involved in oxysterol metabolism.
Rapid hepatic metabolism of 7-ketocholesterol by 11beta-hydroxysteroid dehydrogenase type 1: species-specific differences between the rat, human, and hamster enzyme.
The role of the Stress-Related Anti-Inflammatory Hormones ACTH and Cortisol in Atherosclerosis.
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.
Atrial Fibrillation
Increased expression of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in human atria during atrial fibrillation.
[Atrial 11beta-hydroxysteroid dehydrogenase type 2 expression in rheumatic heart disease patients with or without atrial fibrillation]
Brain Diseases
Low doses of liquorice can induce hypertension encephalopathy.
Brain Ischemia
11beta-hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemia.
Breast Neoplasms
Contribution of protein kinase A and protein kinase C signalling pathways to the regulation of HSD11B2 expression and proliferation of MCF-7 cells.
Expression of the 11beta-hydroxysteroid dehydrogenase type II enzyme in breast tumors and modulation of activity and cell growth in PMC42 cells.
Impairment of the antiproliferative effect of glucocorticosteroids by 11beta-hydroxysteroid dehydrogenase type 2 overexpression in MCF-7 breast-cancer cells.
Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells.
Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking.
Progestin regulation of 11beta-hydroxysteroid dehydrogenase expression in T-47D human breast cancer cells.
The 11beta-hydroxysteroid dehydrogenases: functions and physiological effects.
The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes.
[Diseases caused by adrenal dyshormonogenesis. The concept of minor enzymopathy. The 3 beta-hydroxysteroid dehydrogenase block; its possible importance in the pathogenesis of breast cancer]
Carcinogenesis
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Prereceptor regulation of glucocorticoid action by 11beta-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation.
Carcinoma
11Beta-hydroxysteroid dehydrogenase 1 expression in squamous cell carcinomas of the head and neck.
Expression of 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma.
Carcinoma, Hepatocellular
11 beta-hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma cells is hormonally regulated: a model system for the study of hepatic glucocorticoid metabolism.
C/EBP regulates hepatic transcription of 11beta -hydroxysteroid dehydrogenase type 1. A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways.
Expression of 11beta-hydroxysteroid dehydrogenase type 2 in an ACTH-producing small cell lung cancer.
Carcinoma, Squamous Cell
11Beta-hydroxysteroid dehydrogenase 1 expression in squamous cell carcinomas of the head and neck.
Carcinosarcoma
NAD dependent 11beta-hydroxysteroid dehydrogenase activity in human endometrium and endometrial tumors.
Cardiomegaly
11beta-Hydroxysteroid dehydrogenase in the heart of normotensive and hypertensive rats.
Chronic intermittent hypoxia induces 11beta-hydroxysteroid dehydrogenase in rat heart.
Cardiovascular Diseases
11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization.
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic sindrome.
Influence of aldosterone vs. endothelin receptor antagonism on renovascular function in liquorice-induced hypertension.
Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms.
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.
Tissue-specific adaptive levels of glucocorticoid receptor alpha mRNA and their relationship with insulin resistance.
Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
Choriocarcinoma
Angiotensin II regulates 11beta-hydroxysteroid dehydrogenase type 2 via AT2 receptors.
Effect of cadmium on cortisol production and 11beta-hydroxysteroid dehydrogenase 2 expression by cultured human choriocarcinoma cells (JEG-3).
Effect of pro-inflammatory cytokines on expression and activity of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human term placental trophoblast and human choriocarcinoma JEG-3 cells.
Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells.
Regulation of cytochrome P450 cholesterol side-chain cleavage, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase type 1 and estradiol-17 beta-hydroxysteroid dehydrogenase mRNA levels by calcium in human choriocarcinoma JEG-3 cells.
Retinoic acid stimulates the expression of 11beta-hydroxysteroid dehydrogenase type 2 in human choriocarcinoma JEG-3 cells.
Structure of the VPATPD gene encoding subunit D of the human vacuolar proton ATPase.
Colitis
11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis.
Glucocorticoid availability in colonic inflammation of rat.
Intestinal inflammation modulates expression of 11beta-hydroxysteroid dehydrogenase in murine gut.
Upregulation of 11?-hydroxysteroid dehydrogenase 1 in lymphoid organs during inflammation in the rat.
Colitis, Ulcerative
11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis.
Colorectal Neoplasms
Expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in colorectal cancer.
Congenital Abnormalities
The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes.
Cushing Syndrome
11Beta-Hydroxylase Deficiency and Other Syndromes of Mineralocorticoid Excess as a Rare Cause of Endocrine Hypertension.
A case of cortisol producing adrenal adenoma without phenotype of Cushing's syndrome due to impaired 11beta-hydroxysteroid dehydrogenase 1 activity.
Adipose tissue 11{beta}-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome.
Adipose tissue expression of 11beta-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity.
Apparent mineralocorticoid excess syndrome: an overview.
Cortisol metabolism in the postoperative period after cardiac surgery.
Mechanism of hypertension in Cushing's syndrome: possible role of 11beta-hydroxysteroid dehydrogenase type 2 in kidneys and vascular cells.
Persistent hypokalemia after successful adrenalectomy in a patient with Cushing's syndrome due to ectopic ACTH secretion: possible role of 11beta-hydroxysteroid dehydrogenase inhibition.
Quantitative real-time PCR for the measurement of 11beta-HSD1 and 11beta-HSD2 mRNA levels in tissues of healthy dogs.
Reduced 11beta-hydroxysteroid dehydrogenase type 1 activity in obese boys.
Role of ketoconazole treatment in urinary-free cortisol-to-cortisone and tetrahydrocortisol-to-tetrahydrocortisone ratios in nonectopic Cushing's syndrome.
Role of local 11 beta-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas.
The 83,557insA variant of the gene coding 11?-hydroxysteroid dehydrogenase type 1 enzyme associates with serum osteocalcin in patients with endogenous Cushing's syndrome.
The activity of 11?-hydroxysteroid dehydrogenase type 2 enzyme and cortisol secretion in patients with adrenal incidentalomas.
Uneventful delivery following series of successive treatments for virilized Cushing syndrome due to adrenocortical carcinoma.
Cysts
Implication of cortisol and 11beta-hydroxysteroid dehydrogenase enzymes in the development of porcine (Sus scrofa domestica) ovarian follicles and cysts.
Dementia
Lack of Association of the 11beta-hydroxysteroid dehydrogenase type 1 gene 83,557insA and hexose-6-phosphate dehydrogenase gene R453Q polymorphisms with body composition, adrenal androgen production, blood pressure, glucose metabolism, and dementia.
Depression, Postpartum
Maternal Prenatal Mental Health and Placental 11?-HSD2 Gene Expression: Initial Findings from the Mercy Pregnancy and Emotional Wellbeing Study.
Dermatitis, Contact
Inhibition of skin 11beta-hydroxysteroid dehydrogenase activity in vivo potentiates the anti-inflammatory actions of glucocorticoids.
Diabetes Mellitus
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
11beta-Hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle.
Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure.
Association studies between the HSD11B2 gene (encoding human 11beta-hydroxysteroid dehydrogenase type 2), type 1 diabetes mellitus and diabetic nephropathy.
Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
INCB-13739, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of type 2 diabetes.
Inhibition of human and rat 11beta-hydroxysteroid dehydrogenase type 1 by 18beta-glycyrrhetinic acid derivatives.
Lack of relationship between 11beta-hydroxysteroid dehydrogenase setpoint and insulin sensitivity in the basal state and after 24h of insulin infusion in healthy subjects and type 2 diabetic patients.
Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor.
Regulatory effect of common promoter polymorphisms on the expression of the 11beta-hydroxysteroid dehydrogenase type 1 gene.
Diabetes Mellitus, Experimental
[Adrenocortical and renin-angiotensin systems in dynamics of experimental diabetes].
Diabetes Mellitus, Type 1
?-Cell-Specific Glucocorticoid Reactivation Attenuates Inflammatory ?-Cell Destruction.
Association studies between the HSD11B2 gene (encoding human 11beta-hydroxysteroid dehydrogenase type 2), type 1 diabetes mellitus and diabetic nephropathy.
Diabetes Mellitus, Type 2
11 beta-hydroxysteroid dehydrogenase type 1 promotes differentiation of 3T3-L1 preadipocyte.
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational approaches.
11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics.
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.
11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds.
11beta-Hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle.
2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11beta-hydroxysteriod dehydrogenase type 1.
4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice.
Alteration of 11beta-hydroxysteroid dehydrogenase type 1 in skeletal muscle in a rat model of type 2 diabetes.
Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes.
Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.
beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action.
Blockade of glucocorticoid excess at the tissue level: inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes.
Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.
Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes.
Different expression and distribution of 11beta-hydroxysteroid dehydrogenase type 1 in obese and lean animal models of type 2 diabetes.
Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes.
Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice.
Functional effects of polymorphisms in the human gene encoding 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1): a sequence variant at the translation start of 11 beta-HSD1 alters enzyme levels.
Glucocorticoids and the insulin resistance syndrome.
H6PDH interacts directly with 11beta-HSD1: implications for determining the directionality of glucocorticoid catalysis.
INCB-13739, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of type 2 diabetes.
Increased glucocorticoid receptor and 11{beta}-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice.
Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.
Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition.
Lack of relationship between 11beta-hydroxysteroid dehydrogenase setpoint and insulin sensitivity in the basal state and after 24h of insulin infusion in healthy subjects and type 2 diabetic patients.
Longer HSD11B2 CA-repeat in impaired glucose tolerance and type 2 diabetes.
Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action.
Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor.
Novel non-steroidal inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Physiological roles of 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase.
Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?
Regulatory effect of common promoter polymorphisms on the expression of the 11beta-hydroxysteroid dehydrogenase type 1 gene.
Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains.
Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.
Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Synthesis and biological evaluation of sulfonamidooxazoles and beta-keto sulfones: selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
The 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients with Type 2 Diabetes Inadequately Controlled By Metformin Monotherapy.
The activity of 11?-hydroxysteroid dehydrogenase type 2 enzyme and cortisol secretion in patients with adrenal incidentalomas.
The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans.
The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations.
The Role of 11Beta-Hydroxysteroid Dehydrogenase in Metabolic Disease and Therapeutic Potential of 11Beta-HSD1 Inhibitors.
Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
[Reduction of obesity-related metabolic risk by modulating tissue exposition to cortisol].
Diabetes, Gestational
Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond.
Diabetic Nephropathies
Association studies between the HSD11B2 gene (encoding human 11beta-hydroxysteroid dehydrogenase type 2), type 1 diabetes mellitus and diabetic nephropathy.
Dyslipidemias
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Overexpression of 11beta-Hydroxysteroid Dehydrogenase Type 1 in Hepatic and Visceral Adipose Tissue is Associated with Metabolic Disorders in Morbidly Obese Patients.
Reduced levels of circulating 7alpha-hydroxy-dehydroepiandrosterone in treated adolescent obese patients.
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
Endometrial Neoplasms
NAD dependent 11beta-hydroxysteroid dehydrogenase activity in human endometrium and endometrial tumors.
Fatty Liver
Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats.
Hepatic 11beta-HSD1 mRNA expression in fatty liver and non-alcoholic steatohepatitis.
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Fetal Growth Retardation
11Beta-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction.
Association of serum lipid concentrations, insulin resistance index and catch-up growth with serum cortisol/cortisone ratio by liquid chromatography tandem mass spectrometry in children born small for gestational age.
Corticotropin-releasing hormone stimulates expression of leptin, 11beta-HSD2 and syncytin-1 in primary human trophoblasts.
Differential expression and activity of 11beta-hydroxysteroid dehydrogenase in human placenta and fetal membranes from pregnancies with intrauterine growth restriction.
Ethanol-induced inhibition of fetal hypothalamic-pituitary-adrenal axis due to prenatal overexposure to maternal glucocorticoid in mice.
Fetal growth restriction alters transcription factor binding and epigenetic mechanisms of renal 11{beta}-hydroxysteroid dehydrogenase type 2 in a sex-specific manner.
Glucocorticoid programming.
Glucocorticoids, 11beta-hydroxysteroid dehydrogenase, and fetal programming.
Placental 11beta-hydroxysteroid dehydrogenase type 2 is reduced in pregnancies complicated with idiopathic intrauterine growth Restriction: evidence that this is associated with an attenuated ratio of cortisone to cortisol in the umbilical artery.
Placental 11ss-HSD2 gene expression at birth is inversely correlated with growth velocity in the first year of life after intrauterine growth restriction (IUGR).
Site-specific methylation of placental HSD11B2 gene promoter is related to intrauterine growth restriction.
The 11beta-hydroxysteroid dehydrogenases: functions and physiological effects.
The cortisol-cortisone shuttle in children born with intrauterine growth retardation.
Fibrosarcoma
Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines.
Gallstones
Estimation of ursodeoxycholic acid in human and bear biles using Clostridium absonum 7 beta-hydroxysteroid dehydrogenase.
Genetic Diseases, Inborn
A novel mutation in HSD11B2 causes apparent mineralocorticoid excess in an Omani kindred.
Apparent mineralocorticoid excess syndrome: an overview.
Gestational Trophoblastic Disease
11beta-Hydroxysteroid dehydrogenase activity in pregnancies complicated by hydatidiform mole.
Glaucoma
11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.
11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response.
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension.
Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
Glioblastoma
CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells.
Glomerulonephritis
Reduced 11beta-hydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome.
Glucose Intolerance
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
Cell-type specific regulation of the human 11beta-hydroxysteroid dehydrogenase type 1 promoter.
Diabetic pregnancy in rats leads to impaired glucose metabolism in offspring involving tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 expression.
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.
Influence of placental 11beta-hydroxysteroid dehydrogenase (11beta-HSD) inhibition on glucose metabolism and 11beta-HSD regulation in adult offspring of rats.
Longer HSD11B2 CA-repeat in impaired glucose tolerance and type 2 diabetes.
Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
[Correlations between the hypothalamo-pituitary-adrenal axis and the metabolic syndrome]
Graves Ophthalmopathy
The role of 11beta-hydroxysteroid dehydrogenase 1 in adipogenesis in thyroid-associated ophthalmopathy.
HELLP Syndrome
The transplacental passage of prednisolone in pregnancies complicated by early-onset HELLP syndrome.
Herpes Zoster
Comparative enzymology of 11 beta -hydroxysteroid dehydrogenase type 1 from glucocorticoid resistant (Guinea pig) versus sensitive (human) species.
Histochemical observations on the adrenal gland of bat Vesperugo pipistrellus (Dobson).
Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues.
Juvenile hypertension, the role of genetically altered steroid metabolism.
Hirsutism
Steroid metabolism in metabolic syndrome X.
Hydatidiform Mole
11beta-Hydroxysteroid dehydrogenase activity in pregnancies complicated by hydatidiform mole.
Hyperaldosteronism
11Beta-Hydroxylase Deficiency and Other Syndromes of Mineralocorticoid Excess as a Rare Cause of Endocrine Hypertension.
Genetic determination of human essential hypertension.
Genetics of hypertensive syndrome.
Hyperaldosteronism in pregnancy.
Induction of 11beta-hydroxysteroid dehydrogenase type 2 and hyperaldosteronism are essential for enhanced sodium absorption after total colectomy in rats.
Primary aldosteronism treated by trilostane (3 beta-hydroxysteroid dehydrogenase inhibitor).
Hyperandrogenism
11beta-hydroxysteroid dehydrogenase type 1 deficiency ('apparent cortisone reductase deficiency') in a 6-year-old boy.
11{beta}-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic Syndrome, and Inflammation.
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase.
Hyperglycemia
11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress.
Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance.
Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring.
Glucocorticoid programming.
Glucocorticoids, prenatal stress and the programming of disease.
Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice.
PPARalpha agonists reduce 11beta-hydroxysteroid dehydrogenase type 1 in the liver.
Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice.
The mother or the fetus? 11beta-hydroxysteroid dehydrogenase type 2 null mice provide evidence for direct fetal programming of behavior by endogenous glucocorticoids.
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Hyperinsulinism
Acute in vivo regulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by insulin and intralipid infusions in humans.
MRNA and enzyme activity of hepatic 11beta-hydroxysteroid dehydrogenase type 1 are elevated in C57BL/KsJ-db/db mice.
Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
Hyperkalemia
Licorice: a sweet alternative to prevent hyperkalemia in dialysis patients?
Hyperlipidemias
Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1.
High-throughput screening of 11beta-hydroxysteroid dehydrogenase type 1 in scintillation proximity assay format.
Pathophysiology of metabolic syndrome X and its links to the perinatal period.
Hypertension
11 beta-Hydroxysteroid dehydrogenase.
11?-Hydroxysteroid Dehydrogenase Type 2 Polymorphisms and Activity in a Chilean Essential Hypertensive and Normotensive Cohort.
11beta-hydroxysteroid dehydrogenase activity in human aortic smooth muscle cells.
11Beta-hydroxysteroid dehydrogenase activity in spontaneously hypertensive and Dahl rats.
11beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
11beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension.
11Beta-hydroxysteroid dehydrogenase in the Dahl rat.
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
11beta-Hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension.
A case of pseudoaldosteronism, accompanied with hypocalcemia and exaggerated ACTH response.
A genetic defect resulting in mild low-renin hypertension.
A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
A new polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene.
A novel mutation in HSD11B2 causes apparent mineralocorticoid excess in an Omani kindred.
A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity.
A urine-concentrating defect in 11?-hydroxysteroid dehydrogenase type 2 null mice.
Acute intrarenal administration of cortisol has no effect on renal blood flow in hypertensive individuals.
Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) activity in hypertensive patients.
Analbuminemic Nagase rats: blood pressure response to dietary salt challenge.
Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension.
Angiotensin II regulates 11beta-hydroxysteroid dehydrogenase type 2 via AT2 receptors.
Apparent Mineralocorticoid Excess by a Novel Mutation and Epigenetic Modulation by HSD11B2 Promoter Methylation.
Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state.
Apparent mineralocorticoid excess syndrome: an overview.
Apparent mineralocorticoid excess: report of six new cases and extensive personal experience.
Arginine vasopressin stimulates 11beta-hydroxysteroid dehydrogenase type 2 expression in the mineralocorticosteroid target cells.
Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure.
CA-Repeat polymorphism in intron 1 of HSD11B2 : effects on gene expression and salt sensitivity.
Carbenoxolone damages endothelium and enhances vasoconstrictor action in aortic rings.
Chronic hypoxemia selectively down-regulates 11beta-hydroxysteroid dehydrogenase type 2 gene expression in the fetal sheep kidney.
Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase.
Conditional Deletion of Hsd11b2 in the Brain Causes Salt Appetite and Hypertension.
Cortisol as a mineralocorticoid in human disease.
Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase.
Cortisol metabolism in hypertension.
Cortisol, 11beta-hydroxysteroid dehydrogenases, and hypertension.
Developmental programming of renal glucocorticoid sensitivity and the renin-angiotensin system.
Dopamine and the kidney: a role in hypertension?
Effect of immunosuppressive and other drugs on the cortisol-cortisone shuttle in human kidney and liver.
Effect of licorice on PTH levels in healthy women.
Effects of alcohol on blood pressure and production of vascular aldosterone and corticosterone.
Effects of cholic acid on blood pressure and production of vascular aldosterone and corticosterone.
Effects of glucose on blood pressure and production of vascular aldosterone and corticosterone.
Effects of glycyrrhizin on production of vascular aldosterone and corticosterone.
Effects of spironolactone on systolic blood pressure in experimental diabetic rats.
Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
Enhanced 11beta-hydroxysteroid dehydrogenase activity, the metabolic syndrome, and systemic hypertension.
Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension.
Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression.
Evidence of altered cortisol metabolism in critically ill patients: a prospective study.
Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function.
Extracellular ATP determines 11beta-hydroxysteroid dehydrogenase type 2 activity via purinergic receptors.
Functional adrenocorticotropic hormone receptor in cultured human vascular endothelial cells : possible role in control of blood pressure.
Gene expression of 11beta-hydroxysteroid dehydrogenase type 1 and type 2 in the kidneys of insulin-dependent diabetic rats.
Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks.
Genetic determination of human essential hypertension.
Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations.
Genotype-phenotype correlations of mutations and polymorphisms in HSD11B2, the gene encoding the kidney isozyme of 11beta-hydroxysteroid dehydrogenase.
Glucocorticoid programming.
Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension.
Glucocorticoids and vascular reactivity.
Glucocorticoids, prenatal stress and the programming of disease.
Glycyrrhetinic acid attenuates vascular smooth muscle vasodilatory function in healthy humans.
Glycyrrhetinic acid decreases plasma potassium concentrations in patients with anuria.
Herbal Medicine Containing Licorice May Be Contraindicated for a Patient With an HSD11B2 Mutation.
HSD11B2 CA-repeat and sodium balance.
Hypertension and circulating mRNA for 11beta-hydroxysteroid dehydrogenase type II.
Hypertension and the cortisol-cortisone shuttle.
Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2.
Identification of polymorphisms in the human 11beta-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity.
Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.
In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice.
Influence of aldosterone vs. endothelin receptor antagonism on renovascular function in liquorice-induced hypertension.
Inhibition of 11-beta-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring.
Insulin, CCAAT/enhancer-binding proteins and lactate regulate the human 11?-hydroxysteroid dehydrogenase type 2 gene expression in colon cancer cell lines.
Interaction between an 11betaHSD1 gene variant and birth era modifies the risk of hypertension in Pima Indians.
Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene.
Licorice reduces serum testosterone in healthy women.
Maintenance of maternal diet-induced hypertension in the rat is dependent on glucocorticoids.
Maternal hypertension and progeny blood pressure: role of aldosterone and 11beta-HSD.
Mechanism of hypertension in Cushing's syndrome: possible role of 11beta-hydroxysteroid dehydrogenase type 2 in kidneys and vascular cells.
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.
Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population.
Mutations in the 11 beta-hydroxysteroid dehydrogenase type II enzyme associated with hypertension and possibly stillbirth.
Possible association but no linkage of the HSD11B2 gene encoding the kidney isozyme of 11beta-hydroxysteroid dehydrogenase to hypertension in Black people.
Prevalence of mild apparent mineralocorticoid excess in Mennonites.
Quantitative real-time PCR for the measurement of 11beta-HSD1 and 11beta-HSD2 mRNA levels in tissues of healthy dogs.
Reduced levels of circulating 7alpha-hydroxy-dehydroepiandrosterone in treated adolescent obese patients.
Regulation of 11beta-hydroxysteroid dehydrogenase type 2 by diuretics and the renin-angiotensin-aldosterone axis.
Renal interstitial corticosterone and 11-dehydrocorticosterone in conscious rats.
Renal medullary 11 beta-hydroxysteroid dehydrogenase type 1 in Dahl salt-sensitive hypertension.
Role of cardiovascular aldosterone in hypertension.
Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides.
Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation.
Salt-sensitive men show reduced heart rate variability, lower norepinephrine and enhanced cortisol during mental stress.
Spironolactone effective hypertension in the elderly due to 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) impairment: contributory role of determining serum cortisol/cortisone ratio as a marker of 11beta-HSD2 activity.
Steroid metabolism in metabolic syndrome X.
Structural analysis and evaluation of the 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) gene in human essential hypertension.
Structural analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene in end-stage renal disease.
Structure of the VPATPD gene encoding subunit D of the human vacuolar proton ATPase.
The 11beta-hydroxysteroid dehydrogenases: functions and physiological effects.
The cortisol-cortisone shuttle in children born with intrauterine growth retardation.
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
The hypertensiogenetic steroid 19-nor-progesterone does not influence cortisol inactivation by 11beta-hydroxysteroid dehydrogenase type 2.
The maternal diet during pregnancy programs altered expression of the glucocorticoid receptor and type 2 11beta-hydroxysteroid dehydrogenase: potential molecular mechanisms underlying the programming of hypertension in utero.
The mother or the fetus? 11beta-hydroxysteroid dehydrogenase type 2 null mice provide evidence for direct fetal programming of behavior by endogenous glucocorticoids.
The role of 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes.
Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
Urinary cortisol to cortisone metabolites in hypertensive obese children.
Urinary cortisol/cortisone ratios in hypertensive and normotensive cats.
Variation in placental type 2 11beta-hydroxysteroid dehydrogenase activity is not related to birth weight or placental weight.
[Possible pathogenetic role of 11 beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) gene polymorphisms in arterial hypertension]
[The activity of 11beta-hydroxysteroid dehydrogenase of rat kidney and liver at inherited stress-induced arterial hypertension]
Hypertension, Pregnancy-Induced
Alteration of the activity of the 11beta-hydroxysteroid dehydrogenase in pregnancy: relevance for the development of pregnancy-induced hypertension?
Hyperthyroidism
Comprehensive study of urinary cortisol metabolites in hyperthyroid and hypothyroid patients.
Hypertriglyceridemia
11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues.
Hypoglycemia
Deletion of Hexose-6-phosphate Dehydrogenase Activates the Unfolded Protein Response Pathway and Induces Skeletal Myopathy.
Hypokalemia
Correlation between decrease of 11beta-hydroxysteroid dehydrogenase activity and hypokalemia induced by furosemide in rats.
Cortisol metabolism in hypertension.
Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations.
Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2.
Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.
Persistent hypokalemia after successful adrenalectomy in a patient with Cushing's syndrome due to ectopic ACTH secretion: possible role of 11beta-hydroxysteroid dehydrogenase inhibition.
Severe muscle weakness due to hypokalemia as a manifestation of small-cell carcinoma.
Hypopituitarism
Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
Lack of contribution of 11betaHSD1 and glucocorticoid action to reduced muscle mass associated with reduced growth hormone action.
Lack of regulation of 11beta-hydroxysteroid dehydrogenase type 1 during short-term manipulation of GH in patients with hypopituitarism.
Hypotension
Placental 11beta-HSD2 activity, early postnatal clinical course, and adrenal function in extremely low birth weight infants.
Hypothyroidism
Effects of thyroid hormone (thyroxine) and testosterone on hepatic 11beta-hydroxysteroid dehydrogenase mRNA and activity in pubertal hypothyroid male rats.
Sex-specific effects of growth hormone on hepatic 11beta-hydroxysteroid dehydrogenase activity and gene expression in hypothyroid rats.
Infection
Effect of pro-inflammatory cytokines on expression and activity of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human term placental trophoblast and human choriocarcinoma JEG-3 cells.
Enhancement of cortisol-induced 11beta-hydroxysteroid dehydrogenase type 1 expression by interleukin 1beta in cultured human chorionic trophoblast cells.
Stimulation of 11beta-HSD1 expression by IL-1beta via a C/EBP binding site in human fetal lung fibroblasts.
Inflammatory Bowel Diseases
11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis.
Expression profiles of human 11beta-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases.
Type II 11beta-hydroxysteroid dehydrogenase expression in human colonic epithelial cells of inflammatory bowel disease.
Upregulation of 11?-hydroxysteroid dehydrogenase 1 in lymphoid organs during inflammation in the rat.
Insulin Resistance
11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
11beta-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negatively associated with insulin sensitivity.
11beta-hydroxysteroid dehydrogenase activity in acromegalic patients with normal or impaired carbohydrate metabolism.
11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue and prospective changes in body weight and insulin resistance.
11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
11{beta}-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle.
4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice.
Adipose tissue expression of 11beta-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity.
Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Association between 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population.
Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase.
Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases.
Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central adiposity.
Cortisone induces insulin resistance in C2C12 myotubes through activation of 11beta-hydroxysteroid dehydrogenase 1 and autocrinal regulation.
Deep subcutaneous adipose tissue: a distinct abdominal adipose depot.
Deletion of Hexose-6-phosphate Dehydrogenase Activates the Unfolded Protein Response Pathway and Induces Skeletal Myopathy.
Diabetic pregnancy in rats leads to impaired glucose metabolism in offspring involving tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 expression.
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Effect of voluntary exercise on peripheral tissue glucocorticoid receptor content and the expression and activity of 11beta-HSD1 in the Syrian hamster.
Effects of a high-salt diet on adipocyte glucocorticoid receptor and 11-beta hydroxysteroid dehydrogenase 1 in salt-sensitive hypertensive rats.
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice.
Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss.
Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome.
Gender-specific links between hepatic 11beta reduction of cortisone and adipokines.
Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women.
Glucocorticoid receptor gene expression in adipose tissue and associated metabolic risk in black and white South African women.
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic sindrome.
Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
H6PDH interacts directly with 11beta-HSD1: implications for determining the directionality of glucocorticoid catalysis.
Hepatic glucose regulation and metabolism in adult sheep: effects of prenatal betamethasone.
Hexose-6-phosphate dehydrogenase in the endoplasmic reticulum.
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.
Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice.
In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue.
In vivo activity of 11beta-hydroxysteroid dehydrogenase type 1 and free fatty acid-induced insulin resistance.
Increased glucocorticoid receptor and 11{beta}-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice.
Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome.
Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.
Insulin sensitisation in the treatment of Type 2 diabetes.
Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Lack of relationship between 11beta-hydroxysteroid dehydrogenase setpoint and insulin sensitivity in the basal state and after 24h of insulin infusion in healthy subjects and type 2 diabetic patients.
Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice.
Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity.
Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Minireview: hexose-6-phosphate dehydrogenase and redox control of 11{beta}-hydroxysteroid dehydrogenase type 1 activity.
Modulation of susceptibility to weight gain and insulin resistance in low birthweight rats by treatment of their mothers with leptin during pregnancy and lactation.
MRNA and enzyme activity of hepatic 11beta-hydroxysteroid dehydrogenase type 1 are elevated in C57BL/KsJ-db/db mice.
Overexpression of 11beta-Hydroxysteroid Dehydrogenase Type 1 in Hepatic and Visceral Adipose Tissue is Associated with Metabolic Disorders in Morbidly Obese Patients.
Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins.
Pathophysiology of metabolic syndrome X and its links to the perinatal period.
Physiological roles of 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase.
Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11{beta}-Hydroxysteroid Dehydrogenase Type 1 (11{beta}-HSD1) Activity After Oral Administration of AMG 221, a Selective 11{beta}-HSD1 Inhibitor.
Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?
Reduced 11beta-hydroxysteroid dehydrogenase type 1 activity in obese boys.
Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss.
Reduced levels of circulating 7alpha-hydroxy-dehydroepiandrosterone in treated adolescent obese patients.
Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss.
Regulation of glucocorticoid receptor alpha and beta isoforms and type I 11beta-hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance?
Rosiglitazone decreases 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue.
Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains.
Skeletal muscle 11beta-HSD1 controls glucocorticoid-induced proteolysis and expression of E3 ubiquitin ligases atrogin-1 and MuRF-1.
Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Subcutaneous Abdominal Adipose Tissue Subcompartments: Potential Role in Rosiglitazone Effects.
The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans.
The critical role of the N-terminus of 11beta-hydroxysteroid dehydrogenase type 1, as being encoded by exon 1, for enzyme stabilization and activity.
The Role of 11Beta-Hydroxysteroid Dehydrogenase in Metabolic Disease and Therapeutic Potential of 11Beta-HSD1 Inhibitors.
Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue.
Kidney Failure, Chronic
A new polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene.
Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure.
Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks.
Pediatric renal allograft transplantation does not normalize the increased cortisol/cortisone ratios of chronic renal failure.
Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation.
Structural analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene in end-stage renal disease.
The role of 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
Leprosy
Alteration of the cortisol-cortisone shuttle in leprosy type 1 reactions in leprosy patients in Hyderabad, India.
Leukemia
Differential regulation of 11beta-hydroxysteroid dehydrogenase-1 by dexamethasone in glucocorticoid-sensitive and -resistant childhood lymphoblastic leukemia.
Meeting Report:The 7th ESPE Growth Plate Working Group Symposium - EUROGROP June 27th 2007, Helsinki, Finland.
Liddle Syndrome
Down-regulation of a hepatic transporter multidrug resistance-associated protein 2 is involved in alteration of pharmacokinetics of glycyrrhizin and its metabolites in a rat model of chronic liver injury.
Renal tubular transport and the genetic basis of hypertensive disease.
Lipodystrophy
In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue.
Liver Cirrhosis
Apparent mineralocorticoid excess syndrome: an overview.
Down-regulation of a hepatic transporter multidrug resistance-associated protein 2 is involved in alteration of pharmacokinetics of glycyrrhizin and its metabolites in a rat model of chronic liver injury.
Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension.
Increased apical targeting of renal epithelial sodium channel subunits and decreased expression of type 2 11beta-hydroxysteroid dehydrogenase in rats with CCl4-induced decompensated liver cirrhosis.
Renal sodium retention in cirrhotic rats depends on glucocorticoid-mediated activation of mineralocorticoid receptor due to decreased renal 11beta-HSD-2 activity.
Liver Diseases
Induction of hepatic 11beta-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease.
Liver Diseases, Alcoholic
Induction of hepatic 11beta-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease.
Lung Neoplasms
11Beta-hydroxysteroid dehydrogenase 1 expression in squamous cell carcinomas of the head and neck.
Expression of 11beta-hydroxysteroid dehydrogenase type 2 in an ACTH-producing small cell lung cancer.
Interindividual variability in the expression and NNK carbonyl reductase activity of 11beta-hydroxysteroid dehydrogenase 1 in human lung.
Purification, characterization and NNK carbonyl reductase activities of 11beta-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen.
Malnutrition
Fetal exposure to excess glucocorticoid is unlikely to explain the effects of periconceptional undernutrition in sheep.
Maternal undernutrition during early to midgestation programs tissue-specific alterations in the expression of the glucocorticoid receptor, 11beta-hydroxysteroid dehydrogenase isoforms, and type 1 angiotensin ii receptor in neonatal sheep.
Perinatal maternal undernutrition programs the offspring hypothalamo-pituitary-adrenal (HPA) axis.
Metabolic Diseases
11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function.
A Polygenic Model of the Metabolic Syndrome With Reduced Circulating and Intra-Adipose Glucocorticoid Action.
Alteration in methylation level at 11?-hydroxysteroid dehydrogenase type 2 gene promoter in infants born to preeclamptic women.
Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys.
Development of a high-throughput cell-based assay for 11beta-hydroxysteroid dehydrogenase type 1 using BacMam technology.
Diabetic pregnancy in rats leads to impaired glucose metabolism in offspring involving tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 expression.
Docking-based 3D-QSAR study for 11beta-HSD1 inhibitors.
Down-regulation of adipose 11beta-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease.
Fructose consumption enhances glucocorticoid action in rat visceral adipose tissue.
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic sindrome.
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 by plant extracts used as traditional antidiabetic medicines.
Inhibition of human and rat 11beta-hydroxysteroid dehydrogenase type 1 by 18beta-glycyrrhetinic acid derivatives.
Modulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles.
Obesity and Corticosteroids: 11beta-Hydroxysteroid Type 1 as a Cause and Therapeutic Target in Metabolic Disease.
Selection and optimization of MCF-7 cell line for screening selective inhibitors of 11beta-hydroxysteroid dehydrogenase 2.
Selective inhibition of 11beta-hydroxysteroid dehydrogenase 1 by 18alpha-glycyrrhetinic acid but not 18beta-glycyrrhetinic acid.
The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in the inflammatory response.
The Role of 11Beta-Hydroxysteroid Dehydrogenase in Metabolic Disease and Therapeutic Potential of 11Beta-HSD1 Inhibitors.
Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
Metabolic Syndrome X
Pathophysiology of metabolic syndrome X and its links to the perinatal period.
Mineralocorticoid Excess Syndrome, Apparent
Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p.R186C in the HSD11B2 gene.
[Measurement of free urinary cortisol and cortisone using liquid chromatography associated with tandem mass spectrometry method]
Muscular Atrophy
Lack of contribution of 11betaHSD1 and glucocorticoid action to reduced muscle mass associated with reduced growth hormone action.
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
Myotonic Dystrophy
Glucocorticoid metabolism and adrenocortical reactivity to ACTH in myotonic dystrophy.
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Neoplasm Metastasis
Can licorice lick colon cancer?
Neoplasms
11Beta-hydroxysteroid dehydrogenase 1 expression in squamous cell carcinomas of the head and neck.
11beta-hydroxysteroid dehydrogenases, cell proliferation and malignancy.
Augmentation of 11beta-hydroxysteroid dehydrogenase type 1 in LPS-activated J774.1 macrophages--role of 11beta-HSD1 in pro-inflammatory properties in macrophages.
Can licorice lick colon cancer?
Cortisol is a suppressor of apoptosis in bovine corpus luteum.
CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells.
Cushing's syndrome associated with a nested stromal epithelial tumor of the liver: hormonal, immunohistochemical, and molecular studies.
Deep subcutaneous adipose tissue: a distinct abdominal adipose depot.
Dexamethasone enhances basal and TNF-{alpha}-stimulated production of PAI-1 via the glucocorticoid receptor regardless of 11{beta}-hydroxysteroid dehydrogenase 2 status in human proximal renal tubular cells.
Effect of pro-inflammatory cytokines on expression and activity of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human term placental trophoblast and human choriocarcinoma JEG-3 cells.
Effects of a high-salt diet on adipocyte glucocorticoid receptor and 11-beta hydroxysteroid dehydrogenase 1 in salt-sensitive hypertensive rats.
Effects of Carbenoxolone on the Canine Pituitary-Adrenal Axis.
Expression of 11beta-hydroxysteroid dehydrogenase type 2 in an ACTH-producing small cell lung cancer.
Expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in colorectal cancer.
Expression of glucocorticoid receptor and 11beta hydroxysteroid dehydrogenase in a case of pulmonary epithelioid haemangioendothelioma.
Gender-specific links between hepatic 11beta reduction of cortisone and adipokines.
Glucocorticoid availability in colonic inflammation of rat.
Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension.
Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma.
Inflammatory mediators down-regulate 11beta-hydroxysteroid dehydrogenase type 2 in a human lung epithelial cell line BEAS-2B and the rat lung.
Inhibition of 11beta-hydroxysteroid dehydrogenase eliminates impaired glucocorticoid suppression and induces apoptosis in corticotroph tumor cells.
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Insulin attenuates the stimulatory effects of tumor necrosis factor alpha on 11beta-hydroxysteroid dehydrogenase 1 in human adipose stromal cells.
Insulin, CCAAT/enhancer-binding proteins and lactate regulate the human 11?-hydroxysteroid dehydrogenase type 2 gene expression in colon cancer cell lines.
Local metabolism of glucocorticoids and its role in rat adjuvant arthritis.
Luteinizing hormone induces expression of 11beta-hydroxysteroid dehydrogenase type 2 in rat Leydig cells.
Mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: a tissue microarray and quantitative RT-PCR study.
Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation.
Morphological and immunological characteristics of a rat choriocarcinoma.
NAD dependent 11beta-hydroxysteroid dehydrogenase activity in human endometrium and endometrial tumors.
Pathophysiology of metabolic syndrome X and its links to the perinatal period.
Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines.
Role of local 11 beta-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas.
T cell-mediated inflammation in adipose tissue does not cause insulin resistance in hyperlipidemic mice.
The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist.
The inflammatory response seen when human omental adipose tissue explants are incubated in primary culture is not dependent upon albumin and is primarily in the nonfat cells.
TNF-alpha enhances intracellular glucocorticoid availability.
Tumor necrosis factor alpha and phorbol 12-myristate-13-acetate down-regulate human 11beta-hydroxysteroid dehydrogenase type 2 through p50/p50 NF-kappaB homodimers and Egr-1.
Tumor necrosis factor-alpha upregulates 11beta-hydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-beta in HepG2 cells.
Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer.
Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Upregulation of 11?-hydroxysteroid dehydrogenase 1 in lymphoid organs during inflammation in the rat.
[Diseases caused by adrenal dyshormonogenesis. The concept of minor enzymopathy. The 3 beta-hydroxysteroid dehydrogenase block; its possible importance in the pathogenesis of breast cancer]
Nephrosis
Reduced 11beta-hydroxysteroid dehydrogenase activity in experimental nephrotic syndrome.
Nephrotic Syndrome
Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension.
Reduced 11beta-hydroxysteroid dehydrogenase activity in experimental nephrotic syndrome.
Reduced 11beta-hydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome.
Neurodegenerative Diseases
11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease.
Obesity
1,25-dihydroxyvitamin D3 modulation of adipocyte glucocorticoid function.
11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
11 beta-hydroxysteroid dehydrogenase type 1 promotes differentiation of 3T3-L1 preadipocyte.
11-Beta hydroxysteroid dehydrogenase type 2 expression in white adipose tissue is strongly correlated with adiposity.
11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization.
11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues.
11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational approaches.
11beta-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negatively associated with insulin sensitivity.
11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
11beta-hydroxysteroid dehydrogenase type 1 and obesity.
11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory.
11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease.
11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue and prospective changes in body weight and insulin resistance.
11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.
11beta-hydroxysteroid dehydrogenase type 1 in obesity.
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
11beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation.
11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress.
11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.
11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.
11beta-Hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle.
11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response.
7-oxysterols modulate glucocorticoid activity in adipocytes through competition for 11beta-hydroxysteroid dehydrogenase type.
A novel promoter for the 11beta-hydroxysteroid dehydrogenase type 1 gene is active in lung and is C/EBPalpha independent.
A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis.
Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance.
Activation of the hypothalamic-pituitary-adrenal axis in obesity: cause or consequence?
Adipose tissue 11{beta}-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome.
Adipose tissue expression of 11beta-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity.
Alteration of 11beta-hydroxysteroid dehydrogenase type 1 in skeletal muscle in a rat model of type 2 diabetes.
Association between 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population.
Association studies between microsatellite markers within the gene encoding human 11beta-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism.
Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver.
Cell-type specific regulation of the human 11beta-hydroxysteroid dehydrogenase type 1 promoter.
Charting biologically relevant chemical space: a structural classification of natural products (SCONP).
Comparison of a homology model and the crystallographic structure of human 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) in a structure-based identification of inhibitors.
Conformational flexibility in crystal structures of human 11beta-hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation.
Cortisol metabolism and visceral obesity: role of 11beta-hydroxysteroid dehydrogenase type I enzyme and reduced co-factor NADPH.
Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central adiposity.
Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.
Cortisol--cause and cure for metabolic syndrome?
Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.
Depot-specific messenger RNA expression of 11 beta-hydroxysteroid dehydrogenase type 1 and leptin in adipose tissue of children and adults.
Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1.
Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes.
Diabetic pregnancy in rats leads to impaired glucose metabolism in offspring involving tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 expression.
Diet and the role of 11beta-hydroxysteroid dehydrogenase-1 on obesity.
Differences in associations between HSD11B1 gene expression and metabolic parameters in subjects with and without impaired glucose homeostasis.
Different responsiveness in body weight and hepatic 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 1 mrna to 11beta-HSD inhibition by glycyrrhetinic acid treatment in obese and lean zucker rats.
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes.
Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Docking-based 3D-QSAR study for 11beta-HSD1 inhibitors.
Effects of gonadectomy on glucocorticoid metabolism in obese Zucker rats.
Effects of proportions of dietary macronutrients on glucocorticoid metabolism in diet-induced obesity in rats.
Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model.
Evidence of altered cortisol metabolism in critically ill patients: a prospective study.
Exploring the pathogenesis of IIH: An inflammatory perspective.
Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome.
Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity.
Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Functional characterization of the human 11 beta-hydroxysteroid dehydrogenase 1B (11 beta-HSD 1B) variant.
Functional effects of polymorphisms in the human gene encoding 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1): a sequence variant at the translation start of 11 beta-HSD1 alters enzyme levels.
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
Glucocorticoid metabolism and adrenocortical reactivity to ACTH in myotonic dystrophy.
Glucocorticoid receptor gene expression in adipose tissue and associated metabolic risk in black and white South African women.
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic sindrome.
High-throughput screening of 11beta-hydroxysteroid dehydrogenase type 1 in scintillation proximity assay format.
Hippocampal 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression has a diurnal variability that is lost in the obese Zucker rat.
Hypothalamic regulation of adiposity: the role of 11beta-hydroxysteroid dehydrogenase type 1.
INCB-13739, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of type 2 diabetes.
Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.
Influence of short-term dietary weight loss on cortisol secretion and metabolism in obese men.
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice.
Inhibition of human and rat 11beta-hydroxysteroid dehydrogenase type 1 by 18beta-glycyrrhetinic acid derivatives.
Interaction between an 11betaHSD1 gene variant and birth era modifies the risk of hypertension in Pima Indians.
Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Lack of mutations of type 1 11beta-hydroxysteroid dehydrogenase gene in patients with abdominal obesity.
Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice.
Lessons in obesity from transgenic animals.
Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity.
Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity.
Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action.
Modification of microsomal 11beta-HSD1 activity by cytosolic compounds: glutathione and hexose phosphoesters.
Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice.
Obese Zucker rats have reduced mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 1 expression in hippocampus-implications for dysregulation of the hypothalamic-pituitary-adrenal axis in obesity.
Omental 11beta-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity.
Overexpression of 11beta-Hydroxysteroid Dehydrogenase Type 1 in Hepatic and Visceral Adipose Tissue is Associated with Metabolic Disorders in Morbidly Obese Patients.
Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins.
Physiological roles of 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase.
Preadipocyte 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Is a Keto-Reductase and Contributes to Diet-Induced Visceral Obesity in Vivo.
Prenatal programming of metabolic syndrome in the common marmoset is associated with increased expression of 11ss-hydroxysteroid dehydrogenase type 1.
Quantitative real-time PCR for the measurement of 11beta-HSD1 and 11beta-HSD2 mRNA levels in tissues of healthy dogs.
Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?
Reduced levels of circulating 7alpha-hydroxy-dehydroepiandrosterone in treated adolescent obese patients.
Reduction of hepatic glucocorticoid receptor and hexose-6-phosphate dehydrogenase expression ameliorates diet-induced obesity and insulin resistance in mice.
Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss.
Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines.
Regulatory effect of common promoter polymorphisms on the expression of the 11beta-hydroxysteroid dehydrogenase type 1 gene.
Role of 11-beta-hydroxysteroid dehydrogenase type 1 in differentiation of 3T3-L1 cells and in rats with diet-induced obesity.
Steroid hormones related to 11beta-hydroxysteroid dehydrogenase type 1 in treated obesity.
Steroid metabolism in metabolic syndrome X.
Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Suppression of 11{beta}-hydroxysteroid dehydrogenase type 1 with RNA interference substantially attenuates 3T3-L1 adipogenesis.
Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans.
The critical role of the N-terminus of 11beta-hydroxysteroid dehydrogenase type 1, as being encoded by exon 1, for enzyme stabilization and activity.
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations.
The Role of 11Beta-Hydroxysteroid Dehydrogenase in Metabolic Disease and Therapeutic Potential of 11Beta-HSD1 Inhibitors.
Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
Tissue-specific dysregulation of cortisol metabolism in human obesity.
Tissue-specific increases in 11beta-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women.
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
Tumor necrosis factor-alpha upregulates 11beta-hydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-beta in HepG2 cells.
Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats.
Urinary free cortisone, but not cortisol, is associated with urine volume in severe obesity.
Vitamin A decreases pre-receptor amplification of glucocorticoids in obesity: study on the effect of vitamin A on 11beta-hydroxysteroid dehydrogenase type 1 activity in liver and visceral fat of WNIN/Ob obese rats.
Weight Loss after Gastric Bypass Surgery in Women Is Followed by a Metabolically Favorable Decrease in 11{beta}-Hydroxysteroid Dehydrogenase 1 Expression in Subcutaneous Adipose Tissue.
Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue.
[Reduction of obesity-related metabolic risk by modulating tissue exposition to cortisol].
Obesity, Abdominal
11Beta-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol.
11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds.
Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity.
Association studies between microsatellite markers within the gene encoding human 11beta-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism.
Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver.
Circulating 11beta-hydroxysteroid dehydrogenase type 1 mRNA and cardiovascular risk factors.
Cortisol metabolism and visceral obesity: role of 11beta-hydroxysteroid dehydrogenase type I enzyme and reduced co-factor NADPH.
Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central adiposity.
Cortisol, 11 beta-hydroxysteroid dehydrogenase type 1 and central obesity.
Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1.
Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase.
Enzymology and molecular biology of glucocorticoid metabolism in humans.
Expression of genes related to glucocorticoid action in human subcutaneous and omental adipose tissue.
Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension.
Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
H6PDH interacts directly with 11beta-HSD1: implications for determining the directionality of glucocorticoid catalysis.
Insulin and dexamethasone dynamically regulate adipocyte 11beta-hydroxysteroid dehydrogenase type 1.
Lack of mutations of type 1 11beta-hydroxysteroid dehydrogenase gene in patients with abdominal obesity.
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Pathophysiology of metabolic syndrome X and its links to the perinatal period.
Quantitative measurements of corticosteroids in ex vivo samples using on-line SPE-LC/MS/MS.
Reduced 11beta-hydroxysteroid dehydrogenase type 1 activity in obese boys.
Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss.
Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines.
Testosterone Stimulates Adipose Tissue 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Expression in a Depot-Specific Manner in Children.
The functional consequences of 11beta-hydroxysteroid dehydrogenase expression in adipose tissue.
Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Tissue-specific increases in 11beta-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women.
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
[Correlations between the hypothalamo-pituitary-adrenal axis and the metabolic syndrome]
[Glucocorticoids, 11 beta-hydroxysteroid dehydrogenase type 1, and visceral obesity]
Obesity, Morbid
Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Obstetric Labor, Premature
Effect of pro-inflammatory cytokines on expression and activity of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human term placental trophoblast and human choriocarcinoma JEG-3 cells.
Role of fetal membranes in signaling of fetal maturation and parturition.
Ocular Hypertension
In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eye.
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension.
Oropharyngeal Neoplasms
11Beta-hydroxysteroid dehydrogenase 1 expression in squamous cell carcinomas of the head and neck.
Osteoarthritis
Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation.
Osteolysis
11beta-hydroxysteroid dehydrogenase type 1 expression in periprosthetic osteolysis.
Osteoporosis
11beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone.
11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.
11beta-Hydroxysteroid dehydrogenase: a regulator of glucocorticoid response in osteoporosis.
11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response.
Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines.
Circulating cortisone levels are associated with biochemical markers of bone formation and lumbar spine BMD: the Hertfordshire Cohort Study.
Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone.
Osteosarcoma
Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines.
Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone.
Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation.
Prereceptor regulation of glucocorticoid action by 11beta-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation.
Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss.
Ovarian Cysts
Implication of cortisol and 11beta-hydroxysteroid dehydrogenase enzymes in the development of porcine (Sus scrofa domestica) ovarian follicles and cysts.
Inactivation of glucocorticoids by 11beta-hydroxysteroid dehydrogenase enzymes increases during the meiotic maturation of porcine oocytes.
Ovarian modulators of 11beta-hydroxysteroid dehydrogenase (11beta HSD) activity in follicular fluid from bovine and porcine large antral follicles and spontaneous ovarian cysts.
Ovarian Diseases
Experimental micropolycystic ovarian disease. I. Measurement of body weight, ovarian weight and histochemical activity of 17 beta-hydroxysteroid dehydrogenase.
Pneumonia
Inflammatory mediators down-regulate 11beta-hydroxysteroid dehydrogenase type 2 in a human lung epithelial cell line BEAS-2B and the rat lung.
Polycystic Ovary Syndrome
11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome.
Endogenous inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 do not explain abnormal cortisol metabolism in polycystic ovary syndrome.
Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome.
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase.
Increased 5alpha-reductase and normal 11beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome.
Pre-Eclampsia
11beta-Hydroxysteroid dehydrogenase activity in pregnancies complicated by hydatidiform mole.
11beta-Hydroxysteroid dehydrogenase type 2 in pregnancy and preeclampsia.
Alteration in methylation level at 11?-hydroxysteroid dehydrogenase type 2 gene promoter in infants born to preeclamptic women.
Angiotensin II regulates 11beta-hydroxysteroid dehydrogenase type 2 via AT2 receptors.
Apparent mineralocorticoid excess syndrome: an overview.
Decreased gene expression of 11beta-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia.
Ontogeny of placental structural development and expression of the renin-angiotensin system and 11beta-HSD2 genes in the rabbit.
Prematurity is related to high placental cortisol in preeclampsia.
The transplacental passage of prednisolone in pregnancies complicated by early-onset HELLP syndrome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Differential regulation of 11beta-hydroxysteroid dehydrogenase-1 by dexamethasone in glucocorticoid-sensitive and -resistant childhood lymphoblastic leukemia.
Pregnancy Complications
Maternal depressive symptoms during pregnancy, placental expression of genes regulating glucocorticoid and serotonin function and infant regulatory behaviors.
Ontogeny of placental structural development and expression of the renin-angiotensin system and 11beta-HSD2 genes in the rabbit.
Premature Birth
[Influence of dexamethasone on expression of 11beta-HSD2 in primary cultured cytotrophoblasts from human preterm placenta]
Prostatic Neoplasms
Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines.
Modulation of 11beta-hydroxysteroid dehydrogenase expression by bombesin: a possible mechanism for glucocorticoid resistance in androgen independent prostate cancer.
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Proteinuria
Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function.
Reduced 11beta-hydroxysteroid dehydrogenase activity in experimental nephrotic syndrome.
Pseudohypoaldosteronism
Epidemiologic study of adrenal gland disorders in Japan.
Rheumatic Heart Disease
[Atrial 11beta-hydroxysteroid dehydrogenase type 2 expression in rheumatic heart disease patients with or without atrial fibrillation]
Sarcopenia
Increased skeletal muscle 11?HSD1 mRNA is associated with lower muscle strength in ageing.
Small Cell Lung Carcinoma
Expression of 11beta-hydroxysteroid dehydrogenase type 2 in an ACTH-producing small cell lung cancer.
steroid 21-monooxygenase deficiency
A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia.
Virus Diseases
Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines.
Xanthomatosis, Cerebrotendinous
Evidence for a role of sterol 27-hydroxylase in glucocorticoid metabolism in vivo.
Studies of the mechanism of the increased biosynthesis of cholestanol in cerebrotendinous xanthomatosis. The activity of delta 5-3 beta-hydroxysteroid dehydrogenase.